ZimVie agrees to be acquired by ARCHIMED for $19.00/share; Q2 net sales $116.7M

ZimVie Inc.

Definitive agreement to be acquired by ARCHIMED for $19.00 per share in cash.
Q2 2025 net sales $116.7M, down 0.1% reported, down 2.1% constant currency YoY.
Net loss from continuing ops improved to $(3.8)M vs $(9.6)M in Q2 2024.
Adjusted EBITDA from continuing ops $17.5M, margin 15.0%, up 150 bps YoY.
GAAP diluted EPS $(0.14); adjusted diluted EPS $0.26 on 28.0M shares.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.